Results 1 to 10 of about 15,452 (119)
Neprilysin Inhibitors in Heart Failure
JACC Basic To Translational Science, 2023 Summary: This article provides a contemporary review and a new perspective on the role of neprilysin inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential mechanisms and unanswered questions in certain HF ...
Biykem Bozkurt
exaly +3 more sources
Frontiers in Aging Neuroscience, 2021 Alzheimer’s disease (AD) is pathologically characterized by extracellular beta-amyloid (Aβ) plaques and intraneuronal tau tangles in the brain. A therapeutic strategy aims to prevent or clear these Aβ plaques and the Aβ-degrading enzyme neprilysin is a ...
Christian Humpel
doaj +1 more source
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease [PDF]
Kidney Research and Clinical Practice, 2021 Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), there remains an enormous health problem with high morbidity and mortality over the last few decades.
In-Jeong Cho, Seok-Min Kang
doaj +1 more source
Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients
Frontiers in Cardiovascular Medicine, 2021 Background: Neprilysin inhibition has demonstrated impressive benefits in heart failure treatment, and is the current focus of interest in cardiovascular (CV) and kidney diseases.
Hyeon Seok Hwang +9 more
doaj +1 more source
Soluble neprilysin and survival in critically ill patients
ESC Heart Failure, 2022 Background Critically ill patients admitted to an intensive care unit (ICU) exhibit a high mortality rate irrespective of the initial cause of hospitalization.
Max Lenz +10 more
doaj +1 more source
Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background Neprilysin is a transmembrane endopeptidase involved in the breakdown of a variety of vasoactive peptides and serves as a therapeutic target in heart failure with reduced ejection fraction (HFrEF).
Suriya Prausmüller +8 more
doaj +1 more source
Biomedicines, 2021 Background: Alzheimer’s disease (AD) involves impairment of Aβ clearance. Neprilysin (NEP) is the most efficient Aβ peptidase. Enhancement of the activity or expression of NEP may provide a prominent therapeutic strategy against AD.
Dimitris Matiadis +7 more
doaj +1 more source
Relevance of Neutrophil Neprilysin in Heart Failure
Cells, 2021 Significant expression of neprilysin (NEP) is found on neutrophils, which present the transmembrane integer form of the enzyme. This study aimed to investigate the relationship of neutrophil transmembrane neprilysin (mNEP) with disease severity, adverse ...
Suriya Prausmüller +13 more
doaj +1 more source
Active site mutations change the cleavage specificity of neprilysin. [PDF]
PLoS ONE, 2012 Neprilysin (NEP), a member of the M13 subgroup of the zinc-dependent endopeptidase family is a membrane bound peptidase capable of cleaving a variety of physiological peptides.
Travis Sexton +4 more
doaj +1 more source
BMC Cardiovascular Disorders, 2020 Background Left ventricular remodeling following ST-elevation myocardial infarction (STEMI) is associated with poor outcome, including heart failure (HF).
Damien Legallois +8 more
doaj +1 more source